Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Question for Whalewatcher

<< Previous

Bullboard Posts

Next >>

Comment by C10H12N2on Dec 28, 2021 4:52pm

77 Views

Post# 34266066

RE:RE:RE:Question for Whalewatcher

We hear you. i simply believe you are flat out wrong. you keeo talking about look at other companies. I don't have to. I'm looking at and comprehending the NASDAQ Guidelines. The same guidelines you are continue going outside of to come up with your own theories. including the Andre Uddin hitman guy who pumped Algernon for the PP then dumped on Algernon when it reported it's first topline data. Screw Uddin and the Mackie clan. I'm onto another subject now.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages